FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204264110> ?p ?o ?g. }

• W3204264110 endingPage "80" @default.
• W3204264110 startingPage "76" @default.
• W3204264110 abstract "The European Association of Urology (EAU) prostate cancer guidelines panel recommends risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk of progression or metastatic disease. The rapidly growing availability of PSMA-directed PET imaging will impact prostate cancer staging. We determined the rates of local and metastatic disease in BCR and biochemical persistence (BCP) of prostate cancer stratified by EAU BCR risk groups and BCP. Methods: Patients with BCR or BCP were enrolled under the same prospective clinical trial protocol conducted at 3 sites (n = 1,777 [91%]: UCLA, n = 662 [NCT02940262]; University of California San Francisco, n = 508 [NCT03353740]; University of Michigan, n = 607 [NCT03396874]); 183 patients with BCP from the Universities of Essen, Bologna, and Munich were included retrospectively. Patients with BCR had to have sufficient data to determine the EAU risk score. Multivariate, binomial logistic regression models were applied to assess independent predictors of M1 disease. Results: In total, 1,960 patients were included. Post-radical prostatectomy EAU BCR low-risk, EAU BCR high-risk, and BCP groups yielded distant metastatic (M1) detection in 43 of 176 (24%), 342 of 931 (37%), and 154 of 386 (40%) patients. For postradiotherapy EAU BCR low-risk and EAU BCR high-risk groups, the M1 detection rate was 113 of 309 (37%) and 110 of 158 (70%), respectively. BCP, high-risk BCR, and higher levels of serum prostate-specific antigen were significantly associated with PSMA PET M1 disease in multivariate regression analysis. PSMA PET revealed no disease in 25% and locoregional-only disease in 33% of patients with post-radical prostatectomy or postradiotherapy EAU BCR high risk. Conclusion: Our findings support the new EAU classification; EAU BCR high-risk groups have higher rates of metastatic disease on PSMA PET than do the low-risk groups. Discordant subgroups, including metastatic disease in low-risk patients and no disease in high-risk patients, warrant inclusion of PSMA PET stage to refine risk assessment." @default.
• W3204264110 created "2021-10-11" @default.
• W3204264110 creator A5004763620 @default.
• W3204264110 creator A5006830341 @default.
• W3204264110 creator A5008670523 @default.
• W3204264110 creator A5013755601 @default.
• W3204264110 creator A5020993128 @default.
• W3204264110 creator A5026969717 @default.
• W3204264110 creator A5032425304 @default.
• W3204264110 creator A5033819749 @default.
• W3204264110 creator A5049548593 @default.
• W3204264110 creator A5053795241 @default.
• W3204264110 creator A5059648298 @default.
• W3204264110 creator A5062907808 @default.
• W3204264110 creator A5062997939 @default.
• W3204264110 creator A5067941796 @default.
• W3204264110 creator A5072458448 @default.
• W3204264110 creator A5086087400 @default.
• W3204264110 date "2021-10-07" @default.
• W3204264110 modified "2023-10-02" @default.
• W3204264110 title "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study" @default.
• W3204264110 cites W2591849683 @default.
• W3204264110 cites W2741499688 @default.
• W3204264110 cites W2767249739 @default.
• W3204264110 cites W2790327395 @default.
• W3204264110 cites W2924617625 @default.
• W3204264110 cites W2928931548 @default.
• W3204264110 cites W2955918565 @default.
• W3204264110 cites W2978235428 @default.
• W3204264110 cites W2989413482 @default.
• W3204264110 cites W3013251573 @default.
• W3204264110 cites W3022545744 @default.
• W3204264110 cites W3116647001 @default.
• W3204264110 cites W3125691306 @default.
• W3204264110 cites W3132398728 @default.
• W3204264110 cites W3184299453 @default.
• W3204264110 doi "https://doi.org/10.2967/jnumed.121.262821" @default.
• W3204264110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34620731" @default.
• W3204264110 hasPublicationYear "2021" @default.
• W3204264110 type Work @default.
• W3204264110 sameAs 3204264110 @default.
• W3204264110 citedByCount "14" @default.
• W3204264110 countsByYear W32042641102021 @default.
• W3204264110 countsByYear W32042641102022 @default.
• W3204264110 countsByYear W32042641102023 @default.
• W3204264110 crossrefType "journal-article" @default.
• W3204264110 hasAuthorship W3204264110A5004763620 @default.
• W3204264110 hasAuthorship W3204264110A5006830341 @default.
• W3204264110 hasAuthorship W3204264110A5008670523 @default.
• W3204264110 hasAuthorship W3204264110A5013755601 @default.
• W3204264110 hasAuthorship W3204264110A5020993128 @default.
• W3204264110 hasAuthorship W3204264110A5026969717 @default.
• W3204264110 hasAuthorship W3204264110A5032425304 @default.
• W3204264110 hasAuthorship W3204264110A5033819749 @default.
• W3204264110 hasAuthorship W3204264110A5049548593 @default.
• W3204264110 hasAuthorship W3204264110A5053795241 @default.
• W3204264110 hasAuthorship W3204264110A5059648298 @default.
• W3204264110 hasAuthorship W3204264110A5062907808 @default.
• W3204264110 hasAuthorship W3204264110A5062997939 @default.
• W3204264110 hasAuthorship W3204264110A5067941796 @default.
• W3204264110 hasAuthorship W3204264110A5072458448 @default.
• W3204264110 hasAuthorship W3204264110A5086087400 @default.
• W3204264110 hasBestOaLocation W32042641101 @default.
• W3204264110 hasConcept C121608353 @default.
• W3204264110 hasConcept C126322002 @default.
• W3204264110 hasConcept C126894567 @default.
• W3204264110 hasConcept C143998085 @default.
• W3204264110 hasConcept C151956035 @default.
• W3204264110 hasConcept C170493617 @default.
• W3204264110 hasConcept C2777008409 @default.
• W3204264110 hasConcept C2779134260 @default.
• W3204264110 hasConcept C2779466945 @default.
• W3204264110 hasConcept C2780192828 @default.
• W3204264110 hasConcept C43907098 @default.
• W3204264110 hasConcept C71924100 @default.
• W3204264110 hasConceptScore W3204264110C121608353 @default.
• W3204264110 hasConceptScore W3204264110C126322002 @default.
• W3204264110 hasConceptScore W3204264110C126894567 @default.
• W3204264110 hasConceptScore W3204264110C143998085 @default.
• W3204264110 hasConceptScore W3204264110C151956035 @default.
• W3204264110 hasConceptScore W3204264110C170493617 @default.
• W3204264110 hasConceptScore W3204264110C2777008409 @default.
• W3204264110 hasConceptScore W3204264110C2779134260 @default.
• W3204264110 hasConceptScore W3204264110C2779466945 @default.
• W3204264110 hasConceptScore W3204264110C2780192828 @default.
• W3204264110 hasConceptScore W3204264110C43907098 @default.
• W3204264110 hasConceptScore W3204264110C71924100 @default.
• W3204264110 hasIssue "1" @default.
• W3204264110 hasLocation W32042641101 @default.
• W3204264110 hasLocation W32042641102 @default.
• W3204264110 hasLocation W32042641103 @default.
• W3204264110 hasLocation W32042641104 @default.
• W3204264110 hasOpenAccess W3204264110 @default.
• W3204264110 hasPrimaryLocation W32042641101 @default.
• W3204264110 hasRelatedWork W1967410728 @default.
• W3204264110 hasRelatedWork W2004446515 @default.
• W3204264110 hasRelatedWork W2026113581 @default.
• W3204264110 hasRelatedWork W2072198445 @default.

• next